DRs. Weber and Ross had a debate in which the question of using intralesional agents came up on April 13 at the Healio Hematology/Oncology  Here is a link to an analysis of their positions. In neither case was PV-10 mentioned. I found that somewhat disappointing.
Link to the conference: healio.com
Dr. Weber:
healio.com
NEW YORK – Jeffrey S. Weber, MD, PhD, discusses his academic debate with Merrick I. Ross, MD, regarding the current role of systemic intralesional therapies as a monotherapy.
Weber notes that in an age of increasingly effective systemic therapies for stage IV melanoma, it would be difficult to rationalize the use of intralesional therapy alone in more than select subgroups of patients with dermal metastases only.
Furthermore, Weber asserts that without significant benefit in PFS and OS, local regression is an insufficient substitute to validate continued interest in current intralesional therapies as a monotherapy.
See Video
Dr; Ross:http://www.healio.com/hematology-oncology/melanoma-skin-cancer/news/online/%7B5412cd6a-b18c-457e-9237-7d6d7e94461f%7D/debate-intralesional-systemic-therapy-useful-in-unresected-regionally-metastatic-melanoma-for-local-regional-control
NEW YORK – Merrick I. Ross, MD, discusses his academic debate with Jeffrey S. Weber, MD, PhD, regarding the current role of systemic intralesional therapies.
Ross illustrates that patients with unresectable, multiple, or advanced locally and regionally metastatic melanoma, whose tumors are accessible for direct injection, remain suitable candidates for intralesional therapy, whether or not they have metastatic disease.
While Ross agrees that use of intralesional therapy as a monotherapy would have extremely limited applications, he highlights that one possible use would be among patients with comorbidities who cannot tolerate more aggressive therapies, as intralesional therapies exhibit very few systemic adverse effects.
See Video |
